These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 28495131

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.
    Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L.
    PLoS Pathog; 2013; 9(4):e1003220. PubMed ID: 23592979
    [Abstract] [Full Text] [Related]

  • 3. Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
    Serafini B, Zandee S, Rosicarelli B, Scorsi E, Veroni C, Larochelle C, D'Alfonso S, Prat A, Aloisi F.
    J Neuroimmunol; 2018 Jun 15; 319():9-12. PubMed ID: 29685294
    [No Abstract] [Full Text] [Related]

  • 4. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
    Serafini B, Rosicarelli B, Veroni C, Mazzola GA, Aloisi F.
    J Virol; 2019 Dec 15; 93(24):. PubMed ID: 31578295
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
    Castellazzi M, Delbue S, Elia F, Gastaldi M, Franciotta D, Rizzo R, Bellini T, Bergamaschi R, Granieri E, Fainardi E.
    Dis Markers; 2015 Dec 15; 2015():901312. PubMed ID: 26101453
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.
    Veroni C, Aloisi F.
    Front Immunol; 2021 Dec 15; 12():665718. PubMed ID: 34305896
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.
    Cytotherapy; 2015 Sep 15; 17(9):1280-91. PubMed ID: 26276009
    [Abstract] [Full Text] [Related]

  • 11. The association of Epstein-Barr virus infection with CXCR3+ B-cell development in multiple sclerosis: impact of immunotherapies.
    van Langelaar J, Wierenga-Wolf AF, Samijn JPA, Luijks CJM, Siepman TA, van Doorn PA, Bell A, van Zelm MC, Smolders J, van Luijn MM.
    Eur J Immunol; 2021 Mar 15; 51(3):626-633. PubMed ID: 33152118
    [Abstract] [Full Text] [Related]

  • 12. Higher incidence of Epstein-Barr virus-induced lymphocyte transformation in multiple sclerosis.
    Tørring C, Andreasen C, Gehr N, Bjerg L, Petersen T, Höllsberg P.
    Acta Neurol Scand; 2014 Aug 15; 130(2):90-6. PubMed ID: 24684660
    [Abstract] [Full Text] [Related]

  • 13. Programmed death 1 is highly expressed on CD8+ CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus.
    Cencioni MT, Magliozzi R, Nicholas R, Ali R, Malik O, Reynolds R, Borsellino G, Battistini L, Muraro PA.
    Immunology; 2017 Dec 15; 152(4):660-676. PubMed ID: 28767147
    [Abstract] [Full Text] [Related]

  • 14. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W.
    Proc Natl Acad Sci U S A; 2016 Oct 18; 113(42):E6467-E6475. PubMed ID: 27698133
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
    Iaffaldano P, Viterbo RG, Trojano M.
    J Neurol; 2016 Aug 18; 263(8):1620-5. PubMed ID: 27260295
    [Abstract] [Full Text] [Related]

  • 17. Tissue-resident memory T cells in the multiple sclerosis brain and their relationship to Epstein-Barr virus infected B cells.
    Serafini B, Rosicarelli B, Veroni C, Aloisi F.
    J Neuroimmunol; 2023 Mar 15; 376():578036. PubMed ID: 36753806
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein-Barr virus infection: A hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis.
    Otto C, Hofmann J, Ruprecht K.
    Med Hypotheses; 2016 Jun 15; 91():109-113. PubMed ID: 27142157
    [Abstract] [Full Text] [Related]

  • 20. HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis.
    Jilek S, Schluep M, Harari A, Canales M, Lysandropoulos A, Zekeridou A, Pantaleo G, Du Pasquier RA.
    J Immunol; 2012 May 01; 188(9):4671-80. PubMed ID: 22461701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.